In its 16th year, the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting remains one of the largest meetings in interventional cardiology. Live case demonstrations of interventional procedures remain a hallmark of this meeting, where results of several clinical studies and reviews of topics of interest for practicing interventional cardiologists were also presented. This meeting continues to provide a venue for extensive industry exhibits, and the role of devices used in interventions was prominent. We present the results of key studies presented at this year's meeting and discuss their clinical implications in addition to summarizing the new techniques and topics presented.
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DRUG-ELUTING STENTS
Because of their superiority in reducing restenosis, drugeluting stents (DES) have replaced the use of bare-metal stents (BMS). Multiple studies involving DES including longer-term follow-ups of previously reported trials and results of DES use for higher-risk lesion and patient subsets were presented at this meeting.
TAXUS-IV (two-year results):
The Pivitol, Prospective, Randomized Trial of the Slow-rate Release Polymerbased Paclitaxel-eluting TAXUS Stent-Greg Stone, MD. This study evaluated the efficacy of a paclitaxeleluting stent (PES) in reducing restenosis versus a BMS (1) . The investigators randomized 1,314 patients undergoing elective stenting, with single de novo lesions 10 to 28 mm in length, treatable with one stent in vessels 2.5 to 3.75 mm in diameter. Patients were randomized to a 1-mg/mm 2 slowrelease paclitaxel-eluting Taxus stent (Boston Scientific, Natick, Massachusetts) or a BMS and received clopidogrel for six months. The primary end point was the nine-month rate of ischemia-driven target vessel revascularization (TVR). The two groups were matched, and nine-month TVR and target lesion revascularization (TLR) rates were 12.0% and 11.3% with the BMS and 4.7% and 3.0% with the Taxus stent (risk ratio [RR] ϭ 0.39 and RR ϭ 0.27, both p Ͻ 0.0001), respectively. There was no difference between the two groups in cardiac death, myocardial infarction (MI), or stent thrombosis at nine months. Significant relative risk reductions of 70% to 80% in TLR were seen in most patient and lesion subgroups, including patients with diabetes, smaller vessels, and longer lesions.
Two-year follow-up data were available for 94% of the study cohort and revealed TVR and TLR rates of 21.1% and 17.4% with the BMS and 10.6% and 5.6% with the Taxus stent (RR ϭ 0.50 and RR ϭ 0.32, both p Ͻ 0.0001), respectively. There was no difference between the two groups in cardiac death, MI, or stent thrombosis at two years, whereas relative risk reductions of 60% to 70% in TLR were seen with the Taxus stent in most patient and lesion subgroups, except insulin-requiring diabetics, in whom the difference did not reach statistical significance. Of importance, although stent thrombosis rates were low in both groups ( The Taxus-II trial was among a series of preliminary clinical trials investigating the utility of PES in reducing restenosis. In this trial, the investigators randomized 536 patients with single de novo lesions of 10.5 mm length in a reference vessel of 2.75 mm diameter to a slow-release (n ϭ 131) or moderate-release (n ϭ 135) polymer-based PES and its bare-metal counterpart (n ϭ 270). Six-month results have been presented previously and revealed TLR reduction of 76% in both the currently approved slow-release and non-commercially available moderate-release PES formulations versus their respective controls.
To demonstrate long-term safety and efficacy, two-year clinical, angiographic, and IVUS results of this study were presented at this meeting. Target lesion revascularization was reduced from 15.5% (BMS) to 5.5% (slow-release PES, p ϭ 0.0047) and 3.9% (moderate-release PES, p ϭ 0.0006) at two years. The TLR rates between six months and two years in all three groups remained unchanged (13 Diabetic patients have higher restenosis rates after coronary stenting. In this multicenter trial, the investigators randomized 160 patients (221 lesions) with diabetes mellitus (oral hypoglycemic or insulin-treated) and de novo native coronary artery lesions to the sirolimus-eluting Cypher stent (Cordis, Miami, Florida) versus its BMS counterpart. The two groups were matched for baseline clinical and angiographic characteristics, and one-third of the patients were insulin-treated in both groups. The primary end point of in-stent and in-segment (5 mm proximal and distal to stent edge) late loss in minimum luminal diameter at nine months by quantitative coronary angiography was reduced by 82% (0.44 mm BMS vs. 0.08 mm Cypher stent, p Ͻ 0.0001), and the secondary end point of in-segment restenosis was reduced by 76% (33% BMS vs. 7.7% Cypher stent, p Ͻ 0.0001) with the Cypher stent. These angiographic findings correlated with comparative reductions in TLR and major adverse cardiac event (MACE) (cardiac death, MI, and TLR) rates at nine months (BMS: TLR 31.3%, MACE 36.3%; Cypher stent: TLR 7.5%, MACE 11.3%, p Ͻ 0.0001 for both). Comparative relative risk reductions were noted in both insulinrequiring and oral hypoglycemic-treated diabetics. Arterial Revascularization Therapies Study (ARTS) IIPatrick Serruys, MD. ARTS I was a large, randomized, multicenter trial, which evaluated complete arterial revascularization with coronary artery bypass graft surgery (CABG) versus multivessel stenting (with BMS) in 1,205 patients with multivessel coronary artery disease (CAD). No significant difference in death, stroke, or MI between the two groups was noted, although there was a 17% reduction in 12-month repeat revascularization with CABG but at a higher cost than multivessel PCI (2) . In ARTS II, 607 patients with multivessel CAD were enrolled in a registry and treated with the sirolimus-eluting Cypher stent. This study was designed to compare one-year major adverse cardiac and cerebrovascular event rates between Cypher stent treated patients against the historical control CABG group (n ϭ 600) from ARTS I.
The patients enrolled in ARTS II had a higher prevalence of diabetes, hypertension, and hypercholesterolemia than patients in ARTS I. Periprocedural use of glycoprotein (GP) IIb/IIIa inhibitors, lesion complexity, and frequency of three-vessel stenting, the number of lesions treated/ patient (ARTS II: 3.2, ARTS I-CABG: 2.6, ARTS I-percutaneous coronary intervention [PCI]: 2.5) and stent length (ARTS II: 73 mm; ARTS I-PCI: 48 mm) were all greater in ARTS II. Despite the greater risk and complexity inherent in this ARTS II cohort, 30-day MACE rate was 2.8% compared with 5.3% for the ARTS I-CABG and 9.2% for the ARTS I-PCI groups. Six-month MACE rates were 6.4%, 9.0%, and 20.0%, in the three groups, respectively (p ϭ NS for all comparisons).
IMPLICATIONS. One year ago the results of the Taxus-IV trial were reported and the benefit of PES in all lesion subtypes and patient populations, including diabetics, was found to be clinically significant and consistent. However, longer-term safety and efficacy data were lacking. Two-year results of both the Taxus-II and -IV trials are reassuring in that no late restenosis catch-up or late coronary artery aneurysm formation has been noted with PES. The initial benefit in lower TLR rates remains at two years after the index procedure, resulting in lower MACE rates at two years and confirming the efficacy of PCI with PES as a long-term revascularization strategy. On a cautionary note, among the PES-treated patients in both trials, eight patients (0.9%) were felt to have late stent thrombosis between six months and two years, whereas no BMS-treated patients had late-stent thrombosis in either trial. Although this rate of late-stent thrombosis is low and deemed to be not statistically significant by the investigators, it is extremely concerning, as this is an underappreciated phenomenon. A recent report by McFadden et al. (3) describes late-stent thrombosis in patients treated with both Taxus and Cypher stents and further raises questions regarding long-term safety of both of these DES especially with discontinuation of antiplatelet therapy. These data suggest that longer-term dual antiplatelet therapy with aspirin and clopidogrel than the currently recommended three to six months after DES implantation may be required. The reasons behind latestent thrombosis with DES remain unclear and need further investigation. As the phenomenon has been reported with both of the currently available DES, and the duration of drug elution is significantly different between the two stents, it is unlikely that the duration of drug elution is associated with late-stent thrombosis. The IVUS data would suggest
that poor stent strut apposition with DES is also not responsible for this problem, so an inflammatory response to the underlying polymer (4) or withdrawal of antiplatelet therapy may be the underlying mechanism. Regardless, an intensive after-marketing surveillance of DES should be performed by clinicians, industry, and regulatory bodies to ensure that the restenosis benefit is not counteracted by life-threatening late-stent thrombosis. Both the sirolimus-eluting Cypher and paclitaxel-eluting Taxus stents are superior to BMS in reducing restenosis and TLR (1, 5) . The Diabetes trial presented at this meeting demonstrates that Cypher stents are clearly beneficial in reducing neointimal proliferation in diabetics, and data from the Taxus-IV trial (1) support that the same holds true for Taxus stents. Although these are not comparative data between these two stents, it is reassuring that in a subset of patients with the highest restenosis rate (diabetics), both commercially available DES offer low restenosis rates. Abstracts presented at this and other recent meetings confirm low restenosis rates with Cypher and Taxus stents in patients with long lesions, calcified lesions, chronic total occlusions, bifurcation lesions, and in-stent restenotic lesions. Data from ARTS II demonstrate that in the contemporary treatment of patients with multivessel CAD, stenting with Cypher stents offers six-month clinical outcomes comparable to CABG. Data with DES are accumulating in high-risk restenosis lesions, but as comparative data between various DES are limited, it appears that stent choice continues to be based on cost and stent deliverability. Studies utilizing ABT-578 and everolimus-eluting stents continue to appear promising, demonstrating low late-loss indices and restenosis rates.
ACUTE MYOCARDIAL INFARCTION
Primary PCI is the preferred revascularization modality for patients suffering an acute ST-segment elevation MI (STEMI) and this has resulted in lower mortality rates and infarct sizes for these patients (6) . Recently multiple studies have been designed and completed to evaluate various techniques for myocardial preservation during PCI for STEMI patients. Systemic hypothermia, intracoronary hyperaqueous oxygen, mechanical thrombectomy with the X-sizer catheter (ev3, Plymouth, Minnesota), and distal microvascular protection with the GuardWire (Medtronic, Minneapolis, Minnesota) all proved to be futile in the treatment of patients with STEMI when tested in a randomized clinical trial (7, 8) . Studies presented at this year's TCT meeting addressed an additional adjunctive therapy for treating STEMI patients. AIMI: Angiojet Rheolytic Thrombectomy in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction-Arshad Ali, MD. This trial used Angiojet Rheolytic Thrombectomy (Possis, Minneapolis, Minnesota) prior to PCI for patients suffering from large STEMIs to test whether thrombus extraction prior to PCI leads to reduction in final infarct size. The investigators randomized 480 STEMI patients with anterior or large inferior myocardial infarcts of Ͻ12 h duration to primary PCI or Angiojet Thrombectomy followed by PCI. Patients with left ventricular dysfunction (ejection fraction Ͻ35%), cardiogenic shock, previous CABG, uncontrolled hypertension, major surgery within 6 weeks, stroke within 30 days or GP IIb/IIIa inhibitor contraindication were excluded from the trial. The two groups were matched in baseline clinical characteristics, target vessel revascularized, time to PCI, use of stents and GP IIb/IIIa inhibitors, baseline thrombus burden, and Thrombolysis In Myocardial Infarction (TIMI) flow grade in culprit vessel. However, in the thrombectomy group, total procedural time was prolonged (76 vs. 60 min, p Ͻ 0.0001) and temporary transvenous pacemaker use was greater (58% vs. 16%, p Ͻ 0.0001). Analysis revealed that final TIMI flow grade 3 was achieved in only 92% of patients in the thrombectomy group and in 97% of patients in the standard PCI group (p Ͻ 0.02), with no difference in myocardial blush score, corrected TIMI frame counts, or ST-segment resolution with either strategy. Periprocedural clinical and angiographic complications were comparable in both groups. The primary end point of final infarct size at 14 to 28 days after MI by Tc-99m sestamibi SPECT imaging was higher in the thrombectomy group (12.5 Ϯ 12.1% thrombectomy vs. 9.8 Ϯ 10.9% control, p Ͻ 0.02), and this difference was most pronounced in inferior infarcts (10.2 Ϯ 11.1% thrombectomy vs. 6.5 Ϯ 8.9% control, p Ͻ 0.005), whereas it was not different in anterior infarcts (16.5 Ϯ 13.1% thrombectomy vs. 15.3 Ϯ 12.0% control, p ϭ 0.58). Secondary end point of 30-day MACE (death, Q-wave MI, stroke, urgent CABG, and TLR) was 6.7% in the thrombectomy group and 1.7% in the control group (p Ͻ 0.01), whereas the secondary end point of ejection fraction at 14 to 28 days was the same in both groups (51 Ϯ 12% thrombectomy vs. 52 Ϯ 11% control, p ϭ 0.38). Most importantly, the thrombectomy group had higher 30-day mortality (4.6% thrombectomy vs. 0.8% control, p Ͻ 0.02).
IMPLICATIONS. Recent trials addressing the treatment of patients with STEMI should serve as reminders of the critical need for randomized clinical trials when new devices or therapies are introduced for clinical use. Although intuitively thrombus extraction before PCI in STEMI patients should be effective, the results of the currently reported AIMI trial not only question the routine use of the Angiojet Thrombectomy device for these patients, but question its safety. The increased time to treatment, requirement of adjunctive temporary pacemaker, higher mortality, and larger infarct size in patients treated with this device should lead to the avoidance of this device. With these data in hand, even in the presence of large intracoronary thrombus burden, the X-sizer thrombectomy device or Pronto extraction catheter (Vascular Solutions, Minneapolis, Minnesota) are safer devices to use. In fact, preliminary data from a randomized clinical trial utilizing the Pronto extraction catheter in STEMI patients were presented at TCT and indicated the efficacy of this device without compromising in patient safety (9) . Further analyses from previously reported trials were also presented, and it appears that in selected subgroups of patients both hyperaqueous oxygen and cooling to a body temperature of Ͻ32°F may lead to infarct size reduction. This appears promising and requires further investigation.
CAROTID STENTING
As symptomatic patients with Ͼ50% internal carotid artery stenosis or asymptomatic patients with Ͼ80% stenosis have lower stroke and death rates with carotid endarterectomy (CEA) than medical therapy (10 -12) , most current studies designed to test the safety and efficacy of carotid stenting are enrolling such patients. On the basis of the results of a randomized trial (13) , carotid stenting has been shown to be non-inferior to CEA for patients with high-risk surgical characteristics for CEA. The results of this and other studies have led to the Food and Drug Administration approval of carotid stenting for the treatment of obstructive carotid artery stenosis, and the treatment paradigm is rapidly shifting from CEA to percutaneous stenting. Numerous randomized and registry studies with newer stent and distal protection devices for the treatment of carotid artery stenosis are ongoing, and the results of two such studies were presented at TCT. CABERNET: Carotid Artery Revascularization Using the Boston Scientific FilterWire and the EndoTex NexStent-L. Nelson Hopkins, MD. In this multicenter prospective registry, the investigators enrolled 480 patients with carotid artery stenosis who were high-risk surgical candidates for CEA to carotid stenting with the nitinol self-expanding EndoTex NexStent (Boston Scientific) in conjunction with the FilterWire (Boston Scientific) distal embolic protection. Symptomatic patients with an internal carotid artery stenosis Ͼ50%, or asymptomatic patients with Ͼ80% (ultrasound)/60% (angiography) stenosis and having at least one high-risk comorbidity for CEA were enrolled. The study population was elderly with a mean age of 72.5 Ϯ 8.6 years, 65.2% men, with 79.8% de novo lesions in a majority of asymptomatic patients (75.6%). Procedural success with stent and distal embolic protection was achieved in 96.9% of the patients with stenosis reduction from 83.6% to 6.5%. The primary end point of 30-day major adverse event (MAE) (death: 0.5%, MI: 0.2%, and any stroke: 3.4%) rate was reported to be 3.8%. Major stroke rate was 1.4%, whereas minor stroke rate was 2.0%. MAVERICK II (30-day results): Evaluation of the Medtronic AVE Self-expanding Carotid Stent System in the Treatment of Carotid Stenosis-Stephen R. Ramee, MD. In this prospective multicenter registry, 399 patients with carotid artery stenosis who were at high risk for CEA were enrolled. They were treated with a self-expanding stent Exponent (Medtronic, Minneapolis, Minnesota) and the GuardWire (Medtronic) distal embolic protection system. Although the one-year MAE (death, MI, ipsilateral stroke) rate is the primary end point and these data are still being collected, secondary end points of the study included acute procedural success and 30-day MAE rate. Acute procedural success defined as the successful placement of the stent (with distal embolic protection) with a final residual stenosis of Ͻ30% in the absence of in-hospital MAE, was reported to be 90.1%. Thirty-day MAE rate was 5.3% (death: 1.0%, MI: 2.0%, ipsilateral stroke: 3.3%).
IMPLICATIONS.
Patients who are deemed to be at high risk for surgical complications during CEA include elderly patients (Ͼ80 years old), patients with significant cardiac or pulmonary disease, patients with contralateral carotid occlusion or contralateral laryngeal nerve palsy, previous radical neck surgery or radiation therapy, and restenosis after CEA. Patients with any one of these high-risk characteristics for CEA were enrolled in a randomized clinical trial comparing CEA to carotid stenting, and results of this trial demonstrate that these patients can be successfully treated with percutaneous carotid stenting with results that are not non-inferior to CEA (13) . Data from two different registries presented at this meeting add to the fund of knowledge regarding the safety and short-term efficacy of carotid stenting with newer stents and distal embolic protection devices for high-risk CEA patients. The Carotid Revascularization Endarterectomy versus Stent Trial (CREST) is a National Institutes of Health/National Heart, Lung, and Blood Institute-funded study in which the investigators are randomizing 2,500 patients at low risk for surgical complications during CEA to carotid stenting versus CEA to evaluate both strategies for carotid revascularization in low-risk patients. As distal embolic protection devices are further improved, anticoagulation regimens optimized and plaque characterization improved, further lowering in procedural complication rates and improvement in both shortterm and long-term outcomes can be expected with carotid stenting for all patients.
SAPHENOUS VEIN GRAFT (SVG) INTERVENTIONS
Patients with degenerated SVGs who require percutaneous revascularization are a difficult subset of patients to treat. This is primarily owing to high restenosis rates in SVG lesions and distal embolization of macro-and microparticulate material during interventional treatment of SVGs, resulting in a 30-day MACE (death, MI, emergency CABG, or TLR) rate of 16.5% without distal embolic protection and 9.6% to 11.6% with distal embolic protection (14, 15) . Studies addressing SVG interventions with newer distal embolic protection devices and polytetrafluoroethylene (PTFE)-covered stents were presented at this meeting.
